trending Market Intelligence /marketintelligence/en/news-insights/trending/nbzmofqtbtjayq8ltff6og2 content esgSubNav
In This List

Intec Pharma raises $2M from underwriters of its public offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Intec Pharma raises $2M from underwriters of its public offering

Intec Pharma Ltd. said the underwriters of its public offering partially exercised their overallotment option to buy 400,000 additional shares at $5.25 apiece.

The Israel-based clinical stage biopharmaceutical company received net proceeds of about $2 million from the exercise.

In April, Intec closed its public offering of 6.75 million ordinary shares at $5.25 apiece to raise about $35.4 million in gross proceeds.

Oppenheimer & Co. Inc. acted as the sole book-running manager, while Ladenburg Thalmann and Roth Capital Partners acted as co-managers in the offering.